STRO · NASDAQ
Sutro Biopharma (STRO) Stock Price & Fundamentals
Sutro Biopharma (STRO) closed at $555.66 on Oct 9, 2026, up 0.98% from the previous close of $550.29.
Share price, past year
1Y +29.41%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $555.66 |
| Sep 30, 2026 | $533.27 |
| Aug 31, 2026 | $535.79 |
| Jul 31, 2026 | $521.28 |
| Jun 30, 2026 | $470.74 |
| May 29, 2026 | $489.36 |
| Apr 30, 2026 | $458.76 |
| Mar 31, 2026 | $445.93 |
| Feb 27, 2026 | $457.54 |
| Jan 30, 2026 | $451.98 |
| Dec 31, 2025 | $465.07 |
| Nov 28, 2025 | $482.02 |
| Oct 31, 2025 | $441.44 |
Key statistics
- Market cap
- $9.21B
- P/E (TTM)
- —
- EPS (TTM)
- −$17.33
- Revenue (TTM)
- $45.70M
- Net income (TTM)
- −$180.64M
- Shares outstanding
- 16.6M
- Dividend yield
- —
- 52-week range
- $429.39 – $555.66
Sutro Biopharma's market cap is $9.21B, based on a share price of $555.66 and 16.6M shares outstanding as of Jun 30, 2026.
Financials
Sutro Biopharma reported revenue of $102.48M for fiscal 2025, up 65.18% from fiscal 2024.
Sutro Biopharma reported a net loss of $191.09M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $102.48M | +65.2% | −$191.09M | −186.5% | −$22.49 | — |
| FY2024ended Dec 31, 2024 | $62.04M | −59.6% | −$227.46M | −366.6% | −$29.40 | — |
| FY2023ended Dec 31, 2023 | $153.73M | +126.8% | −$106.79M | −69.5% | −$17.80 | — |
| FY2022ended Dec 31, 2022 | $67.77M | +9.5% | −$119.20M | −175.9% | −$23.50 | — |
| FY2021ended Dec 31, 2021 | $61.88M | +44.8% | −$105.54M | −170.6% | −$22.90 | — |
| FY2020ended Dec 31, 2020 | $42.72M | 0.0% | −$32.13M | −75.2% | −$9.90 | — |
| FY2019ended Dec 31, 2019 | $42.74M | +11.2% | −$119.20M | −278.9% | −$24.30 | — |
| FY2018ended Dec 31, 2018 | $38.42M | −25.8% | −$35.32M | −91.9% | −$61.30 | $11.13M |
| FY2017ended Dec 31, 2017 | $51.74M | −13.4% | −$19.69M | −38.1% | −$439.50 | −$40.39M |
| FY2016ended Dec 31, 2016 | $59.73M | — | $1.70M | 2.9% | $0.00 | −$17.55M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $9.84M | −$38.53M | −$2.33 |
| Q1 FY2026ended Mar 31, 2026 | $14.52M | −$38.48M | −$2.94 |
| Q4 FY2025ended Dec 31, 2025 | $11.65M | −$46.76M | −$5.36 |
| Q3 FY2025ended Sep 30, 2025 | $9.69M | −$56.86M | −$6.70 |
| Q2 FY2025ended Jun 30, 2025 | $63.75M | −$11.50M | −$1.35 |
| Q1 FY2025ended Mar 31, 2025 | $17.40M | −$75.97M | −$9.08 |
| Q4 FY2024ended Dec 31, 2024 | $14.81M | −$72.44M | −$11.70 |
| Q3 FY2024ended Sep 30, 2024 | $8.52M | −$48.79M | −$5.90 |
Company profile
- Name
- Sutro Biopharma, Inc.
- Ticker
- STRO
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Biological Products, (No Diagnostic Substances)
- Headquarters
- 111 Oyster Point Blvd., South San Francisco, CA 94080
- Fiscal year ends
- December
- SEC CIK
- 0001382101
Recent SEC filings
- Aug 12, 2026
- Aug 12, 2026
- Jun 8, 2026
- May 14, 2026
- May 14, 2026
- Mar 23, 2026
- Mar 23, 2026
- Feb 10, 2026
Frequently asked questions
What is Sutro Biopharma's stock price?
Sutro Biopharma (STRO) closed at $555.66 on Oct 9, 2026, up 0.98% from the previous close of $550.29.
What is Sutro Biopharma's market cap?
Sutro Biopharma's market cap is $9.21B, based on a share price of $555.66 and 16.6M shares outstanding as of Jun 30, 2026.
How much revenue does Sutro Biopharma make?
Sutro Biopharma reported revenue of $102.48M for fiscal 2025, up 65.18% from fiscal 2024.
Does Sutro Biopharma pay a dividend?
Sutro Biopharma's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from Sutro Biopharma, Inc.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures